Compare McKesson Corporation (MCK) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs BlackRock TCP Capital Corp — how do they compare? McKesson Corporation trades at $892.49 (market cap $105.14B), while BlackRock TCP Capital Corp trades at $3.91 (market cap $327.64M). The key difference: McKesson Corporation is far larger — about 320.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (19.46%). Which is the better fit depends on your goals.
| MCK | TCPC | |
|---|---|---|
Market Cap | $105.14B | $327.64M |
Sector | Health | Financials |
52-Week High | $995.69 | $7.26 |
52-Week Low | $659.01 | $3.13 |
Enterprise Value | $111.67B | — |
Dividend Yield | 0.42% | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
TCPC trades at $3.88, down 1.52% today, with a bullish technical trend and neutral oscillators. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company announced a $523 million portfolio sale to reduce leverage. The stock shows a high P/S ratio of 70.7 but trades below book value with a P/B of 0.59. Dividends of $0.17 per share are scheduled for H1 and H2 2026.
Outlook is mixed: strategic moves and dividend yield near 8.8% offer value, but negative revenue, net losses, and a class action lawsuit pose risks. Analyst consensus leans hold, with 30.8% buy ratings. Further upside depends on successful execution of the strategic review and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
